Restoring the DHA levels in the brains of zellweger patients
- 293 Downloads
Patients with the Zellweger syndrome and its variants have very low levels of docosahexaenoic acid (DHA) in the brain, retina, and other tissues. Such a marked DHA deficiency could be related to the pathogenesis of peroxisomal disorders. Therefore, restoring the DHA levels in these patients can probably improve the clinical course of the disease. With this rationale, 20 patients with generalized peroxisomal disorders have been treated to date with DHA ethyl ester, at daily doses of 100–500 mg, for variable periods of time. Treatment has been always accompanied by a nutritious diet, normal for the age, in order to provide all the necessary nutrients and avoid a polyunsaturated fatty acid (PUFA) imbalance. The most constant improvement has been normalization of the DHA levels and liver function. Vision has improved in about half the patients and muscle tone has generally increased. Magnetic resonance imaging (MRI) examination revealed improvement of myelination in 9 patients. Significantly, the clinical improvement has been most marked in those patients who started the treatment before 6 mo of age. Biochemically, the plasma very long-chain fatty acids (VLCFA) 26:0 and 26:1n-9 decreased markedly despite the complete diet provided. In erythrocytes, the plasmalogen ratio 18:0DMA/18:0 increased in most cases, and sometimes even normalized. All these beneficial effects suggest that DHA deficiency plays a fundamental role in the pathogenesis of peroxisomal disease. Because DHA accretion is maximal during early brain development, it is essential to initiate the treatment as soon as possible. Otherwise, restoration of brain DHA levels and prevention of further damage will not be possible.
Index EntriesZellweger syndrome docosahecaenoic acid arachidonic acid plasmalogens DHA therapy
Unable to display preview. Download preview PDF.
- Bush R. A., Malnoe A., Reme C. E., and Williams T. P. (1994) Dietary deficiency of N-3 fatty acids alters rhodopsin content and function in the rat. Invest. Ophtalmol. Vis. Sci. 355, 91–100.Google Scholar
- Dobbing J. (1968) Vulnerable periods in developing brain, in Applied Neurochemistry (Davison A. N. and Dobbing J., eds.), Blackwell, Edinburgh, pp. 287–316.Google Scholar
- Lazarow P. B. and Moser H. W. (1997) Disorders of peroxisome biogenesis, in The Metabolic Basis of Inherited Disease (Scriver C. R., Beaudet A. L., Sly W. S., and Valle D., eds.), 7th CD-ROM edition, McGraw-Hill, New York, records 38,247–38,973.Google Scholar
- Moser A. B., Singh I., Brown F. R. III, Solish, G. I., Kelly R. I., Benke P. J., and Moser H. W. (1984) The cerebro-hepato-renal (Zellweger) syndrome: increased levels and impaired degradation of very long chain fatty acids and their use in prenatal diagnosis. N. Engl. J. Med. 310, 1141–1146.PubMedCrossRefGoogle Scholar
- Martinez M. (1992b) Severe changes in polyunsaturated fatty acids in the brain, liver, kidney, and retina in patients with peroxisomal disorders, in Neurobiology of Essential Fatty Acids (Bazan N, ed.), Plenum, New York, pp. 347–359.Google Scholar
- Martinez M. (1992d) Treatment with docosahexaenoic acid favorably modifies the fatty acid composition of erythrocytes in peroxisomal patients, in New Developments in Fatty Acid Oxidation (Coates P. M. and Tanaka K., eds.), Wiley-Liss, New York, pp. 389–397.Google Scholar
- Martinez M. (1998) Docosahexaenoic acid ethyl ester as a treatment for patients with generalized peroxisomal disorders, in Lipids in Infant Nutrition (Huang Y. S. and Sinclair A. J., eds.), AOCS Press, Champaign, Illinois, pp. 29–38.Google Scholar
- Martinez M., Conde C., and Ballabriga A. (1974) Some chemical aspects of human brain development. II. Phosphoglyceride fatty acids. Pediatr. Res. 8, 91–102.Google Scholar
- Martinez M., Vazquez E., García Silva M. T., Manzanares J., Bertran J. M., Castell F., et al. (1998) Tratamiento de las enfermedades peroxisomales generalizadas con etil ester del cido docosahexaenoico. Rev. Neurología 28, S59-S64.Google Scholar
- Purpura D. P. (1975) Morphogenesis of the visual cortex in the preterm infant, in Growth and Development of the Brain (Brazier M. A. B., ed.), Raven Press, New York, pp. 33–49.Google Scholar
- Rotstein N. P., Politi L. E., and Aveldaño M. I. (1998) Docosahexaenoic acid promotes differentiation of developing photoreceptors in culture. Invest. Opthalmol. Vis. Sci. 39, 2750–2758.Google Scholar